Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,189.41 -44.25 (-3.59%)
Official Closing Price Updated: 7:00 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Veeva Systems Q2 Earnings Call Highlights ↗
Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs ↗
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity. 
Via Benzinga
News headline image
Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week ↗
Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound. 
Via Benzinga
News headline image
VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology
Via AB Newswire
Topics Artificial Intelligence
Eli Lilly (NYSE:LLY) Demonstrates High-Growth Leadership and Momentum ↗
Via Chartmill
Eli Lilly (NYSE:LLY): A Dividend Quality Pick with Sustainable Growth ↗
Via Chartmill
Eli Lilly (NYSE:LLY) Shows Strong Growth and a Compelling Technical Setup ↗
Via Chartmill
News headline image
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
Via AB Newswire
Topics Artificial Intelligence
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Is It Too Late to Buy Eli Lilly? Billionaire Ken Griffin Doesn't Think So. He Nearly Quadrupled His Stake in the Pharma Stock in Q2. ↗
Eli Lilly looks like a strong long-term investment thanks to its booming obesity drugs and Alzheimer's treatment, and to Billionaire Ken Griffin's investment. 
Via The Motley Fool
News headline image
Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus ↗
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility. 
Via The Motley Fool
Topics ETFs
News headline image
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗
Duquesne Family Office has beefed up its healthcare holdings. 
Via The Motley Fool
News headline image
2 Stocks That Could Capitalize on the GLP-1 Boom ↗
They aren't the most prominent names in the GLP-1 space, but they are worth a second look. 
Via The Motley Fool
News headline image
Which Healthcare ETF Is the Better Buy: Vanguard's VHT or iShares' IXJ? ↗
VHT charges low fees and holds more than 400 stocks for broader diversification. IXJ's portfolio of 110 holdings includes international exposure -- but comes at a higher cost. 
Via The Motley Fool
Topics ETFs
News headline image
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
2 Profitable Stocks with Solid Fundamentals and 1 We Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
Topics Economy Energy
News headline image
3 Growth Stocks That Could Skyrocket in the Second Half of 2026 ↗
Here are three growth leaders with strong tailwinds: Arista Networks, Micron, and Eli Lilly. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can ↗
Could this little-known biotech be a hidden gem? 
Via The Motley Fool
News headline image
FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors? ↗
Here's how Invesco's concentrated pharma play compares to Fidelity's diversified approach to healthcare stocks. 
Via The Motley Fool
Topics ETFs
News headline image
Billionaire Ken Griffin Just Loaded Up on Eli Lilly Stock. Should You? ↗
Griffin's Q2 move is already paying off nicely. 
Via The Motley Fool
News headline image
2 Biotech Stocks Shaping Up for Major Breakouts ↗
Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts. 
Via MarketBeat
Topics ETFs
News headline image
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? ↗
IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk. 
Via The Motley Fool
Topics ETFs
News headline image
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years ↗
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.41% on an annualized basis producing an average annual return of 36.72%. Currently, Eli Lilly has a market capitalization of... 
Via Benzinga
News headline image
Stock Split Watch: Is Eli Lilly (LLY) Stock Next? ↗
Shares recently traded at $1,280 each, so a split wouldn't be surprising. 
Via The Motley Fool
News headline image
In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech? ↗
VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk. 
Via The Motley Fool
Topics ETFs
News headline image
There’s a Black Market for Eli Lilly’s Unapproved GLP-1 Drug. Here’s Why That’s Bullish ↗
Can anyone challenge Eli Lilly in the weight loss space? 
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy? ↗
XBI is up nearly 80% over the past year, but has experienced a much larger maximum drawdown over the past five years. IHE has delivered steadier returns and offers a higher dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Could Eli Lilly Be Worth More Than SpaceX by the End of 2026? ↗
These two stocks both have market caps of more than $1 trillion, but Eli Lilly's valuation is supported by strong financials. 
Via The Motley Fool
News headline image
Absci (ABSI) Q2 2026 Earnings Call Transcript ↗
Biotech extends runway to 2028 with $100M financing and Eli Lilly deal. 
Via The Motley Fool
Topics Earnings
News headline image
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
News Provided by USA News Group on behalf of MindWalk Holdings Corp. 
From USA News Group
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.